Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.34 |
| ▸ | MAT2A | P31153 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 9/20 | 0.33 |
| ▸ | USP14 | P54578 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20114572 | 1.00 | PTGER4 (0.34) | PTGER4MAT2ATDP2USP14BRD4 | |
| SCHEMBL20156176 | 0.93 | PTGER4 (0.36) | PTGER4TDP2GABRA1GABRG2GABRB3 | |
| SCHEMBL20150338 | 0.91 | PTGER4 (0.34) | PTGER4MAT2ATDP2USP14BRD4 | |
| SCHEMBL20114542 | 0.91 | PTGER4 (0.34) | PTGER4MAT2ATDP2USP14BRD4 | |
| SCHEMBL20114551 | 0.90 | TDO2 (0.35) | PTGER4USP14GABRA1GABRG2GABRB3 | |
| SCHEMBL20114694 | 0.89 | PTGER4 (0.38) | PTGER4GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL20156218 | 0.88 | PTGER4 (0.39) | PTGER4GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL20114573 | 0.87 | CASP3 (0.38) | MAT2ATDP2USP14GABRA1GABRG2 | |
| SCHEMBL20150380 | 0.87 | PTGER4 (0.37) | PTGER4GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL20996886 | 0.87 | CYP1A2 (0.38) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134686-A1 | ORGANIC MOLECULES, ESPECIALLY FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134686-A1 | ORGANIC MOLECULES, ESPECIALLY FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | OR10J3, EPCAM, F12 | PTGER4 1809/4885MAT2A 2283/4885TDP2 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.